Xiaojun Wang is an accomplished Associate Vice President with over 20 years of experience in drug discovery, specifically focusing on metabolic diseases and diabetes complications. They have led numerous projects that advanced to clinical candidates during their tenure at Eli Lilly and Company, where they held several significant positions from 2014 to 2022. Prior to this, they served in research roles at Abbott Labs and completed postdoctoral research at Northwestern University. Xiaojun earned a Ph.D. in Biochemistry from Chicago Medical School and holds a BS in Biochemistry and an MSc in Immunology.
This person is not in any teams
This person is not in any offices